GCA
IBB icon

Gradient Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Gradient Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,434
Closed -$209K – 153
2024
Q3 		$209K Buy
+1,434
New +$207K 0.07% 145

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Gradient Capital Advisors's IBB Position: Q4 2024 in Review

Gradient Capital Advisors sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 1,434 shares — an estimated $209K sold.

Gradient Capital Advisors first reported a position in IBB in Q3 2024 and held it in 1 quarter. The position peaked at $209K in Q3 2024. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

  • Gradient Capital Advisors reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
  • Gradient Capital Advisors sold 1,434 iShares Biotechnology ETF shares in Q4 2024, an estimated $209K.
  • Gradient Capital Advisors first reported a position in iShares Biotechnology ETF in Q3 2024 and held it in 1 quarter.
  • Gradient Capital Advisors's iShares Biotechnology ETF position peaked at $209K in Q3 2024.
  • 874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Gradient Capital Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.